The globally renowned biopharmaceutical company Aberdeen established its headquarters in the United States in 2013, and simultaneously established its headquarters in China with its headquarters in Shanghai. As a company that split from Abbott and grew independently for 10 years, Abbott has been deeply involved in the field of immunotherapy for 10 years, and has performed quite well in the 1.0 era. Starting this year, Aberville will usher in a growing 2.0 era, and companies will also go to the CIIE three times to bring more heavyweight products to the Chinese market, presenting a unique color and radiance of biopharmaceutical companies on the CIIE stage.
Three Visits to Jinbo
Make a debut with two heavyweight products
In 2020, Aberdeen participated in the CIIE for the first time, and this is the third time he has visited the CIIE. Ms. Dong Lijun, Vice President and General Manager of ABV China, stated that the 6th CIIE is of great significance to enterprises, and it is also a comprehensive offline CIIE held after the pandemic. The theme of the enterprise exhibition booth is set to be 'Chasing Light with Ai, Lightening Life'.
The exhibition stand with the concept of "life time and space" as its main concept has an extraordinary meaning. In an imaginative and extraordinary time and space, Abervi and global partners "Chase the Light with Ai" explore innovative therapies that light up life day and night, solving various difficult and complex human diseases.
From innovative products born in extraordinary laboratories to landing in China on the "acceleration" track of the CIIE, from innovative drugs that allow Chinese patients to "see" to innovative drugs that are "usable", it signifies the inheritance of the fate between Abbreville and CIIE.
In fact, "Life Time and Space" is also a continuation and sublimation of the concepts of "Extraordinary Laboratory" and "Future Star Group" exhibited by Abbott in the first two sessions of the CIIE, reflecting Abbott's characteristics as a leading global research and development biopharmaceutical enterprise - innovation, leadership, and win-win.
Three visits to the CIIE will showcase multiple innovative products in the five major therapeutic fields of immunology, oncology, neuroscience, ophthalmology, and aesthetics. This time, it will also make its debut as a heavyweight product from the field of immunotherapy - SKYRIZITM (Lisheng Qizhu monoclonal antibody), as well as a heavyweight product from the field of hematology and oncology - EPKINLYTM (Eckerrituximab). These two heavyweight products are also exemplary examples of companies pursuing First in class and Best in class.
Huge spillover effects
Bringing Gospel to More Patients
The stage of entering the Expo has a huge spillover effect for Aberdeen. When attending the 2020 conference, the company brought in Ruifu and Weikelai, both of which were only displayed in pictures and had not yet been launched in China. The CIIE allows companies to see their exhibits transform from pictures to medicine boxes and physical objects, ultimately benefiting patients and even entering the entire process of medical insurance, fulfilling their commitment to a healthy China.
In December 2020, Weikelai successfully passed the accelerated review and was approved for listing within 10 months. Ruifu (Upatinib) is even more typical, as it is the first oral JAK inhibitor approved in China and the first oral selective JAK inhibitor approved in China for the treatment of atopic dermatitis, rheumatoid arthritis, ulcerative colitis, and Crohn's disease. The R&D of Ruifu has achieved complete synchronization of research and development, registration, and listing between China and Europe and America.
Ruifu was approved for its first indication in China in February 2022. In January of this year, the three earliest approved indications were included in the national medical insurance, which has benefited more patients and greatly improved their accessibility. Prior to the 6th CIIE, Ruifu was approved for two new indications on the same day: ankylosing spondylitis (AS) and radiation negative axial spinal arthritis (nr axSpA). Therefore, Ruifu has also become the first and only oral targeted therapy approved in China for the treatment of psoriasis arthritis and covering the entire course of axSpA (axial spinal arthritis). This means that within 20 months of its launch, Ruifu has been approved with 7 indications. In the future, there will be more indications for product approval.
As for the launch of Weikelai, it can be said that it has broken the deadlock of decades of drug unavailability in related blood tumors and brought the treatment of acute myeloid leukemia (AML) into the era of targeted therapy. In 2023, only one can enter medical insurance, which is currently the only targeted drug in the AML field that has been included in medical insurance.
Dong Lijun stated that Aberville has fulfilled its original commitment to China: patients' costs are more affordable, medication is more accessible, and helping them see more hope for survival!
Synchronize globally
Clinical research incubates more new products
Aberdeen's transition from the 1.0 era to the 2.0 era is like transitioning from a baby to adulthood. Dong Lijun stated that this means that the enterprise is more mature and will also take on more responsibilities. In August of this year, the State Council issued 24 regulations to attract foreign investment. For young Aberdeen, the 2.0 era will continue to soar with the "east wind" and seek more long-term development in the Chinese market.
The "China Cooperation Day" has been held for three consecutive years by Aberdeen. During the cooperation day, Chinese governments, enterprises, academic institutions, associations, and other organizations at all levels jointly participate in expanding diversified cooperation, from drug research and development, commercialization to academic progress, and jointly build a medical innovation ecosystem through multi-party cooperation.
China is the second largest market in the world that Abervey is very concerned about, and its proportion in the global layout is also increasing day by day. By 2030, Alberto will have 30 new indications and products on the market. At present, the company has invested more than 200 R&D personnel in China, with nearly 70 clinical research projects under research or planned. Approximately 85% of the three phase projects of ABV China are global multi center projects, indicating that China is becoming increasingly important in ABV's global research and development. Based on this, the number of new products that will be launched simultaneously with the world in the future will gradually increase, which is also a realistic interpretation of China's "acceleration". Aberdeen is also actively participating in Shanghai's efforts to create a global hub for biopharmaceutical innovation. Abervi hopes to use innovation as the "golden key" to open the door of opportunity and prosperity for Shanghai's biopharmaceutical industry.
In the future, Aberville will continue to deepen its efforts in the five major fields of immunology, oncology, neuroscience, ophthalmology, and aesthetics. At the same time, it will collaborate with China's industrial chain, capital chain, and innovation chain to explore the blue ocean together.